Grosse Chance WKN 931506


Seite 14 von 14
Neuester Beitrag: 02.05.10 14:39
Eröffnet am: 04.04.07 09:33 von: plusquamperf. Anzahl Beiträge: 342
Neuester Beitrag: 02.05.10 14:39 von: _bbb_ Leser gesamt: 24.451
Forum: Hot-Stocks   Leser heute: 0
Bewertet mit:
3


 
Seite: < 1 | ... | 8 | 9 | 10 | 11 | 12 | 13 |
>  

2212 Postings, 6388 Tage duffyduckwie gehts hier weiter?

 
  
    #326
27.06.08 09:10
keinerlei meldung...  

620 Postings, 4518 Tage toni800der Kurs

 
  
    #327
30.06.08 18:20

Klebt bei 21 US Cents.

 

So wirds wahrscheinlich auch eine ganze Weile bleiben?!

 

MfG 

 

5662 Postings, 4625 Tage _bbb_:)

 
  
    #328
30.06.08 18:24
Zumindest stabiler Kurs, runter gehts nimmer mehr IMO !
Also wenn ich kohle hätte würde ich gern nachlegen...  

4951 Postings, 4609 Tage 0815ax_bbb_ - Hurra, wir leben noch! (Umsatz zieht an)

 
  
    #329
02.07.08 19:25
USA: bis dato 82T$
Angehängte Grafik:
gtec.gif
gtec.gif

620 Postings, 4518 Tage toni800ja in der Tat!

 
  
    #330
03.07.08 18:13

Die Börsenstimmung ist relativ mies!

Aber Genesis hält gut die Stellung zwischen 20-22 US Cents !

 

Mfg 

 

4951 Postings, 4609 Tage 0815axFrage in die Diskussionsrunde -

 
  
    #331
06.07.08 19:42
...in wie weit kann/wird sich dies auf GTEC auswirken (Werbung / Gewinne ...)
Angehängte Grafik:
beijing_2008_olympics_logo.png
beijing_2008_olympics_logo.png

620 Postings, 4518 Tage toni800Hallo 0815ax ,

 
  
    #332
07.07.08 17:47

Wie meinst du das?

Ist GTEC denn vor Ort da oder als Verpfleger dort? 

 

MfG 

 

5662 Postings, 4625 Tage _bbb_NEWS !

 
  
    #333
1
15.07.08 17:13
Genesis Pharmaceuticals Announces SFDA Approval for Radix Isatidis Dispersible Tablets
Date : 07/15/2008 @ 11:04AM
Source : PR Newswire
<< Back

Genesis Pharmaceuticals Announces SFDA Approval for Radix Isatidis Dispersible Tablets





LAIYANG, China, July 15 /Xinhua-PRNewswire-FirstCall/ -- Genesis Pharmaceuticals Enterprises, Inc. (OTC:GTEC) (BULLETIN BOARD: GTEC) ("Genesis" or the "Company"), a leading pharmaceutical company in the People's Republic of China, today announced that the Company received approval from the Chinese State Food and Drug Administration ("SFDA") to start producing and distributing Radix Isatidis Dispersible Tablets.

Radix Isatidis is an herbal-based traditional Chinese medicine used to cure viral influenza. Radix Isatidis is very popular in China because people there believe it has fewer side affects than western medicines. Most Radix Isatidis products are in powder form, which has to be dissolved in hot water. Genesis will be the only company in China to manufacture Radix Isatidis in dispersible tablet form. Radix Isatidis Dispersible Tablets will be more convenient to take, easier to absorb and are more stable than Radix Isatidis products in powder form.

Radix Isatidis Dispersible Tablets will be sold over the counter in pharmacies, a rapidly growing distribution channel for drugs in China. The Company will start distributing Radix Isatidis Dispersible Tablets within three months, and will make this medicine widely available to customers throughout China.

Annual sales of Radix Isatidis in China are estimated to be over US$1.43 billion. The Company estimates that its sales of Radix Isatidis Dispersible Tablets in fiscal year 2009 ending June 30, 2009 will be approximately US$4.2 million and an estimated US$10 million in fiscal year 2010.

Genesis has all of manufacturing equipment needed to produce Radix Isatidis Dispersible Tablets, and has concluded its marketing research and planning for this new product. The Company estimates that its first year working capital and marketing expenses will be approximately US$1.0 million.

"We are pleased to receive approval from the SFDA to produce and distribute Radix Isatidis Dispersible Tablets," said Mr. Cao Wubo, Chairman and CEO of Genesis Pharmaceuticals Enterprises. "We will distribute this new drug through our existing nationwide marketing and distribution network, and believe it will quickly become popular among a wide range of customers, from young to old people."

About Genesis Pharmaceuticals Enterprises, Inc.

Genesis Pharmaceuticals Enterprises, Inc. is a U.S. public company engaged in the research, development, production, marketing and sales of pharmaceutical products in the People's Republic of China. Its operations are located in Northeast China in an Economic Development Zone in Laiyang City, Shandong province. Genesis is a major pharmaceutical company in China producing tablets, capsules, and granules for both western and Chinese herbal- based medical drugs.

Safe Harbor Statement

Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to introduce, manufacture and distribute new drugs. Actual results may differ materially from anticipated or predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

For more information, please contact:

Genesis Pharmaceuticals Enterprises, Inc.

Ms. Elsa Sung, CFO Tel: +1-954-727-8436 Email: Web: http://www.genesis-china.net/

CCG Elite Investor Relations, Inc.

Mr. Crocker Coulson, President Tel: +1-646-213-1915 Email: Web: http://www.ccgelite.com/

DATASOURCE: Genesis Pharmaceuticals Enterprises, Inc.


CONTACT: Ms. Elsa Sung, CFO of Genesis Pharmaceuticals Enterprises, Inc.,

+1-954-727-8436, or ; Mr. Crocker Coulson, President of

CCG Elite Investor Relations, Inc., +1-646-213-1915, or



Web site: http://www.genesis-china.net/

http://www.ccgelite.com/  

4951 Postings, 4609 Tage 0815ax...was lange dauert, wird endlich gut...

 
  
    #334
15.07.08 17:55
good news!

5662 Postings, 4625 Tage _bbb_@ax

 
  
    #335
15.07.08 18:00
Ja genau...darauf haben wir gewartet ! :)  

2212 Postings, 6388 Tage duffyduckwie gut ist die meldung wirklich

 
  
    #336
15.07.08 21:28

620 Postings, 4518 Tage toni800hallo duffy,

 
  
    #337
15.07.08 22:02

diese meldung ist sehr gut!

einfach lesen :-)

 

gruß 

 

2212 Postings, 6388 Tage duffyduck.

 
  
    #338
15.07.08 22:12
der kurs springt aber nicht so an.

 

5662 Postings, 4625 Tage _bbb_NEWS!

 
  
    #339
23.07.08 17:37
Genesis Pharmaceuticals Announces New Board Member and Forms Committees





LAIYANG, China, July 23 /Xinhua-PRNewswire-FirstCall/ -- Genesis Pharmaceuticals Enterprises, Inc. (OTC:GTEC) (BULLETIN BOARD: GTEC) ("Genesis" or the "Company"), a leading pharmaceutical company in the People's Republic of China, held a Board of Directors meeting on July 18, 2008 at which a new Board member was appointed to serve on the Board of Directors of the Company, and an Audit Committee and a Compensation Committee were formed.

Mr. Michael Marks was appointed to the Company's Board of Directors on July 18, 2008. Since 2007, he has served as an independent director of China Housing & Land Development, Inc., a property developer in China. In 2006, Mr. Marks became President of Middle Kingdom Alliance Corp., a publicly traded Special Purpose Acquisition Corporation active in China. In 2003, Mr. Marks founded the China practice of Sonnenblick Goldman, a real estate investment bank, and served as its Managing Director in China until 2007. In 2001, he founded B2Globe, providing technology solutions to international internet businesses in Asia. In 1999, he co-founded Metro Corporate Training in Shanghai to offer training and management development, and was its Chief Executive Officer until 2001. During his nine-year tenure in China, Mr. Marks has had a role as advisor, banker or principal in over $2 billion of transactions. From 1998 to 1999, Mr. Marks worked as a management consultant with Horwath Asia Pacific in Australia and China. From 1995 to 1998, Mr. Marks worked in the audit, corporate finance and advisory divisions of PricewaterhouseCoopers in South Africa. Mr. Marks received a Bachelor of Commerce (Honors) in 1994 and Masters of Commerce in 1997 from the University of the Witwatersrand in Johannesburg, South Africa. In 1998, he graduated with a Bachelor of Arts (Psychology) degree from the University of South Africa. In 1997, Mr. Marks became a Chartered Accountant in South Africa, and a Fellow of the Association of International Accountants in the United Kingdom in 1999. He speaks fluent Mandarin, French and English.

The Board of Directors accepted the resignations of Mr. Zhang Yihua and Mr. Rodrigo Arboleda. The resignations of Mr. Zhang and Mr. Arboleda from the Company's Board of Directors were not the result of any disagreements with the Company on any matter relating to the Company's operations, policies or practices.

"I look forward to working with Genesis," stated Michael Marks. "Having participated in the growth of a number of companies in China, I know that Genesis is a company with a tremendous future. I am excited to be a part of its development."

The Board of Directors authorized and approved creation of an Audit Committee that will oversee matters relating to the Company's financial reporting. Qualifying as an "audit committee financial expert" in compliance with applicable SEC and current stock exchange rules and regulations, Michael Marks was appointed as the Chairman of the Audit Committee. Each member of the Audit Committee is "independent" as defined in Section 10A of the Securities Exchange Act of 1934.

The Board of Directors also authorized and approved creation of a Compensation Committee that will, among other things, make recommendations to the Board of Directors concerning salaries and incentive compensation for the Company's officers. Feng Xiaowei was appointed as the Chairman of the Compensation Committee. Each member of the Compensation Committee is "independent" as defined in Section 10A of the Securities Exchange Act of 1934.

"We are pleased to welcome Michael Marks to serve as a member of our Board of Directors. We believe that he will make an immediate and valuable contribution to the work of our Board," said Mr. Cao Wubo, Chairman and CEO of Genesis Pharmaceuticals Enterprises. "At its last meeting, our Board of Directors created an Audit Committee and Compensation Committee composed of independent Board members. We believe that the establishment of these committees will help to assure investors that Genesis is fully committed to the highest possible standards of corporate governance."

About Genesis Pharmaceuticals Enterprises, Inc.

Genesis Pharmaceuticals Enterprises, Inc. is a U.S. public company engaged in the research, development, production, marketing and sales of pharmaceutical products in the People's Republic of China. Its operations are located in Northeast China in an Economic Development Zone in Laiyang City, Shandong province. Genesis is a major pharmaceutical company in China producing tablets, capsules, and granules for both western and Chinese herbal- based medical drugs.

Safe Harbor Statement

Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to introduce, manufacture and distribute new drugs. Actual results may differ materially from anticipated or predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

For more information, please contact:

Genesis Pharmaceuticals Enterprises, Inc.

Ms. Elsa Sung, CFO Tel: +1-954-727-8436 Email: Web: http://www.genesis-china.net/

CCG Investor Relations, Inc.

Mr. Crocker Coulson, President Tel: +1-646-213-1915 Email: Web: http://www.ccgir.com/

DATASOURCE: Genesis Pharmaceuticals Enterprises, Inc.


CONTACT: Ms. Elsa Sung, CFO of Genesis Pharmaceuticals Enterprises, Inc.,

+1-954-727-8436, or ; Mr. Crocker Coulson, President of

CCG Elite Investor Relations, Inc., +1-646-213-1915, or



Web site: http://www.genesis-china.net/

http://www.ccgelite.com/

 

4951 Postings, 4609 Tage 0815ax...wichtige Daten im August

 
  
    #340
03.08.08 18:14

Thursday August 14th Forms 13F and 10-Q for filers with quarters ending June 30, 2008(45 days after period end)

Friday August 15th Notification of Late Filing (NT 10-Q) for Form 10-Q/10QSB, if 10-Q/10QSB is not filed on time(Due on the business day after the 10-Q due date.)

Wednesday August 20th Extended deadline for filing a Form 10-Q/10QSB after filing a NT 10-Q (Due 5 calendar days after original filing due date)

620 Postings, 4518 Tage toni800Hallo zusammen!

 
  
    #341
1
12.08.08 19:55

Seid ihr alle noch investiert?

 

Mein anlagehorizont ist mehrer jahre.

 

sollte eigentlich nicht schief gehen.

 

Gruß

Tonci 

 

5662 Postings, 4625 Tage _bbb_FYI ! Hier gehts zum aktuellen Thread...

 
  
    #342
02.05.10 14:39
Heisst jetzt  JGBO !
WKN: A0RNJBISIN: US47737R1014 Symbol: JGBO

http://www.ariva.de/..._Pharmaceuticals_ehem_GNPH_A0RNJB_JGBO_t376817  

Seite: < 1 | ... | 8 | 9 | 10 | 11 | 12 | 13 |
>  
   Antwort einfügen - nach oben